Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of ...

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly hopes that Mounjaro will take the baton from Trulicity, and extend the company's dominance in the GLP-1 space. Trulicity raked in $1.9 billion in sales in the second quarter ...

Eli Lilly's top-launching new meds Trulicity and Taltz didn't deliver ... "will likely raise eyebrows," Divan noted ahead of the company's Q1 earnings call. And sure enough, on Tuesday’s ...

Eli Lilly and Company discovers, develops ... Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza ...

executive vice president and CFO of Eli Lilly, said in a Dec. 13earnings call. The company said it plans to double its manufacturing capacity for Mounjaro and Trulicity by the end of 2023.

Eli Lilly(NYSE:LLY ... volatile due to challenges in fulfilling high demand. The company also saw a 31% decline in worldwide Trulicity revenue in Q2, impacting its overall financial performance ...

Eli Lilly (LLY 2.28%) is a leading pharmaceutical company. It has developed several blockbuster products, including Trulicity (type 2 diabetes), Taltz (plaque psoriasis), and Jardiance (blood sugar).